Related references
Note: Only part of the references are listed.Progenetix: 12 years of oncogenomic data curation
Haoyang Cai et al.
NUCLEIC ACIDS RESEARCH (2014)
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Helga Thorvaldsdottir et al.
BRIEFINGS IN BIOINFORMATICS (2013)
Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing
Ellen Heitzer et al.
CANCER RESEARCH (2013)
Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing
K. C. Allen Chan et al.
CLINICAL CHEMISTRY (2013)
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Ned Calonge et al.
GENETICS IN MEDICINE (2013)
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
Emanuele Valtorta et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer
Ellen Heitzer et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Single circulating tumor cell sequencing for monitoring
Martina Auer et al.
ONCOTARGET (2013)
Circulating tumor cells and DNA as liquid biopsies
Ellen Heitzer et al.
GENOME MEDICINE (2013)
Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?
Evelyn Kidess et al.
GENOME MEDICINE (2013)
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
Ellen Heitzer et al.
GENOME MEDICINE (2013)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
The road to resistance: EGFR mutation and cetuximab
Alberto Bardelli et al.
NATURE MEDICINE (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Tim Forshew et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
Rebecca J. Leary et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?
Alessandro Inno et al.
CLINICAL COLORECTAL CANCER (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine
G. Smith et al.
BRITISH JOURNAL OF CANCER (2010)
Use of Cancer-Specific Genomic Rearrangements to Quantify Disease Burden in Plasma from Patients with Solid Tumors
David J. McBride et al.
GENES CHROMOSOMES & CANCER (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Rebecca J. Leary et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2009)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Nuclear EGFR contributes to acquired resistance to cetuximab
C. Li et al.
ONCOGENE (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
CGHweb: a tool for comparing DNA copy number segmentations from multiple algorithms
Weil Lai et al.
BIOINFORMATICS (2008)
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab:: A fluorescent in situ hybridization study
Nicola Personeni et al.
CLINICAL CANCER RESEARCH (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2008)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the Anti-EGFR monoclonal antibody cetuximab
Yang Lu et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Andrea Sartore-Bianchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Detection and quantification of mutations in the plasma of patients with colorectal tumors
F Diehl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Analysis of array CGH data:: from signal ratio to gain and loss of DNA regions
P Hupé et al.
BIOINFORMATICS (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Circular binary segmentation for the analysis of array-based DNA copy number data
AB Olshen et al.
BIOSTATISTICS (2004)
Share Paper
